drugset / Trial / NCT05487755
Investigational and Comparative Study in the Management of Diabetic Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to investigate and compare the safety and efficacy of selective (PDE5) enzyme inhibitor; tadalafil and non selective (PDE) inhibitor; pentoxifylline in diabetic nephropathy to improve glucose metabolism, lipid profile and decrease albuminuria.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2023-03-01
- Completion
- 2023-09-01
Publications
- Background Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond). 2009 Mar;116(6):479-92. doi: 10.1042/CS20080394.
- Background Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013 Feb;124(3):139-52. doi: 10.1042/CS20120198.
- Hegazy SK, Amaar WA, Hegab WSM. Tadalafil versus pentoxifylline in the management of diabetic kidney disease: a randomized clinical trial. Diabetol Metab Syndr. 2024 Jun 24;16(1):138. doi: 10.1186/s13098-024-01363-3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentoxifylline | Small molecule | 400 mg | Oral |
| Subject | Tadalafil | Small molecule | 20 mg | Oral |